Calendar

pharmadog

Week of Apr 13, 2026

Apr 16, 2026approval91d agoBRIMONIDINE TARTRATE — FDA approvalLumify

Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC

full page →Lumify →fda approvals ↗

Apr 16, 2026approval91d agoSELEXIPAG — FDA approvalSELEXIPAG

Sponsor: RK PHARMA. Form: TABLET. Route: ORAL

full page →SELEXIPAG →fda approvals ↗

Apr 16, 2026approval91d agoDUPIXENT (DUPILUMAB) — FDA approvaldupilumab

Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

full page →dupilumab →fda approvals ↗

Apr 16, 2026grant91d agoJOHNS HOPKINS UNIVERSITY — Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequela...Johns Hopkins University

NS grant. $633,378. PI: Alba Miranda Azola

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF WASHINGTON — Development of molecular tools and mouse models to study neglected Sindbis vi...University of Washington

AI grant. $88,250. PI: Jennifer Lynn Hyde

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF MARYLAND BALTIMORE — Epigenetic regulation of neo-sex chromosomes in filarial parasites

AI grant. $440,211. PI: Julie Dunning Hotopp

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF TEXAS ARLINGTON — CONNECT: Cohort-Oriented Network kNowledgebase for Enhanced CollaboraTion

ES grant. $605,091. PI: Yike Shen

full page →nih reporter ↗

Apr 16, 2026grant91d agoGEORGETOWN UNIVERSITY — Epigenetic Biomarkers in Glioblastoma

NS grant. $429,000. PI: NAGI G AYAD

full page →nih reporter ↗

Apr 16, 2026grant91d agoEMORY UNIVERSITY — Understanding Multidrug-Resistant Pathogen Infections and their Treatment wit...Emory University

AI grant. $161,244. PI: TERESA GIL GIL

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF PENNSYLVANIA — Metabolic Imaging Using Hyperpolarized Agents at Tracer ConcentrationsUniversity of Pennsylvania

CA grant. $415,623. PI: STEPHEN J KADLECEK

full page →nih reporter ↗

Apr 16, 2026grant91d agoBOSTON CHILDREN'S HOSPITAL — Molecular Mechanisms of Aire in Transcriptional RegulationBoston Children's Hospital

AI grant. $267,000. PI: Qianxia Zhang

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF PITTSBURGH AT PITTSBURGH — The molecular and physiologic effects of calcineurin inhibitors on WNK body b...

DK grant. $769,882. PI: Cary Ragan Boyd-Shiwarski

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIV OF MASSACHUSETTS MED SCH WORCESTER — Examining the Effectiveness of School-based Health Centers (SBHCs) to Improve...

NR grant. $3,480,544. PI: Michelle Trivedi

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF MICHIGAN AT ANN ARBOR — Volatile Organic Compound Impacts on Immune Functions During Pregnancy: Molec...

ES grant. $795,869. PI: Sean M Harris

full page →nih reporter ↗

Apr 16, 2026grant91d agoLOUISIANA STATE UNIV HSC SHREVEPORT — The role of ZBP1 in controlling HSV-1 pathogenesis

AI grant. $660,723. PI: Hongyan Guo

full page →nih reporter ↗

Apr 16, 2026grant91d agoICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — Determinants of viral assembly and infectivity within the Ebola virus VP24 pr...

AI grant. $843,182. PI: Christopher F Basler

full page →nih reporter ↗

Apr 16, 2026grant91d agoUNIVERSITY OF CALIFORNIA, SAN DIEGO — The effects and mechanisms supporting psilocybin induced pain reliefUniversity of California San Diego

AT grant. $788,967. PI: ADAM L. Halberstadt

full page →nih reporter ↗

Apr 17, 2026approval90d agoSODIUM ACETATE — FDA approvalSODIUM ACETATE

Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS

full page →SODIUM ACETATE →fda approvals ↗

Apr 17, 2026approval90d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Apr 17, 2026approval90d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Apr 17, 2026approval90d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Apr 17, 2026approval90d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Apr 17, 2026approval90d agoVALPROIC ACID — FDA approvalVALPROIC ACID

Sponsor: QUAGEN. Form: SYRUP. Route: ORAL

full page →VALPROIC ACID →fda approvals ↗

Apr 17, 2026approval90d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →carbamazepine ER →fda approvals ↗

Apr 17, 2026approval90d agoCALCIPOTRIENE — FDA approvalPrasco LLC

Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL

full page →fda approvals ↗

Apr 17, 2026approval90d agoESOMEPRAZOLE MAGNESIUM — FDA approvalesomeprazole magnesium DR

Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL

full page →esomeprazole magnesium DR →fda approvals ↗

Apr 17, 2026approval90d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL

full page →LAMOTRIGINE →fda approvals ↗

Apr 17, 2026approval90d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL

full page →LAMOTRIGINE →fda approvals ↗

Apr 17, 2026approval90d agoTETRACYCLINE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals of New York LLC

Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

Apr 17, 2026approval90d agoTETRACYCLINE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals of New York LLC

Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

Apr 17, 2026grant90d agoUNIVERSITY OF WASHINGTON — Mentoring patient-oriented research on point-of-care diagnostics for infectio...University of Washington

AI grant. $209,758. PI: Paul K Drain

full page →nih reporter ↗

Apr 17, 2026grant90d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Assessing multi-site feasibility of an integrated whole-body hyperthermia and...University of California San Francisco

AT grant. $601,259. PI: Ashley E. Mason

full page →nih reporter ↗

Apr 17, 2026grant90d agoUNIVERSITY OF SOUTH FLORIDA — Aligning Circuit-Directed Rehabilitation with HPA Axis for Improved TBI Recovery

NS grant. $568,920. PI: Theresa Currier Thomas

full page →nih reporter ↗

Apr 17, 2026grant90d agoNORTHWESTERN UNIVERSITY AT CHICAGO — Disrupting the Peri-necrotic Engine of Immunosuppression in GlioblastomaNorthwestern University

CA grant. $496,357. PI: DANIEL J BRAT

full page →nih reporter ↗

Apr 17, 2026grant90d agoMASSACHUSETTS GENERAL HOSPITAL — Toolkit for Optimal Pain Management in the Emergency Department: A mind-body ...Massachusetts General Hospital

AT grant. $170,640. PI: Julia E. Hooker

full page →nih reporter ↗

Apr 17, 2026grant90d agoRUTGERS BIOMEDICAL AND HEALTH SCIENCES — Novel Pediatric TB Diagnostics using Host and Microbial Biomarkers

AI grant. $210,302. PI: William Evan Johnson

full page →nih reporter ↗

Apr 17, 2026grant90d agoUNIVERSITY OF MICHIGAN AT ANN ARBOR — Remote Loading of Melanocortin and GLP-1 Peptides in Polymers for Treatment o...

DK grant. $231,000. PI: Roger D. Cone

full page →nih reporter ↗

Apr 17, 2026grant90d agoRESEARCH TRIANGLE INSTITUTE — Development of Neuromedin Receptor 2 antagonists as Novel Analgesics

NS grant. $230,562. PI: Thuy Nguyen

full page →nih reporter ↗

Apr 17, 2026grant90d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Analyzing the Distribution, Effectiveness, and Implementation of Wildfire Smo...University of California San Francisco

ES grant. $117,747. PI: Rebecca Sugrue

full page →nih reporter ↗

Week of Apr 20, 2026

Apr 20, 2026approval87d agoCANAGLIFLOZIN — FDA approvalCANAGLIFLOZIN

Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

full page →CANAGLIFLOZIN →fda approvals ↗

Apr 20, 2026approval

Week of Apr 27, 2026

Apr 27, 2026phase 1 initiation80d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

full page →pembrolizumab →source: globaldata

Apr 27, 2026phase 1 initiation

← prev

page 1 of 8

Week of Apr 13, 2026

Week of Apr 20, 2026

Week of Apr 27, 2026